US-based contract development and manufacturing organisation (CDMO), Cambrex, has started construction on a new research and development facility at its site in Milan, Italy, involving an investment of $30-mn.
The new facility will add analytical development and process R&D capabilities, alongside upgrades to several production plants at the site, and is expected to be completed in the second half of 2027. Cambrex has also acquired additional land adjoining the site to allow for future expansion.
The investment coincides with the 80th anniversary of the Cambrex Profarmico Milano site, which has supported pharmaceutical development and manufacturing for the company’s global client base since its founding. The Milan team recently held an event to mark the occasion.
The Cambrex Profarmico Milano site, which marks its 80th anniversary this year, has a distinguished legacy of supporting pharmaceutical development and manufacturing for its global client base. The Milan team recently gathered to celebrate this milestone, reflecting on eight decades of scientific achievement and dedication to advancing human health.
Mr. Claudio Russolo, Chief Operating Officer at Cambrex, said the new facility reflected the expertise built by the Milan team over eight decades, and that the site has served as a hub for pharmaceutical manufacturing in Europe. He said the expansion represented investment in new technologies and capabilities as well as in the company’s people and partners. “By expanding R&D capabilities in Milan, Cambrex is strengthening its ability to address the increasing complexity of today’s small molecule therapies,” he added.


21 August, 2026 11:47:09 IST 
















